Core Viewpoint - EUDA Health Holdings Limited has shifted from a joint venture to a commercial distribution arrangement with Guangdong Cell Biotech, enhancing its access to advanced stem cell therapies and regenerative medicine in Southeast Asia [1][2][4]. Company Overview - EUDA Health Holdings Limited is a Singapore-based property management services provider and a leading non-invasive healthcare provider in Singapore and Malaysia, focusing on transforming the health and wellness landscape through innovative non-invasive treatments [5]. Strategic Partnership Update - The collaboration with Guangdong Cell Biotech will allow EUDA to market and sell stem cell therapies in Singapore and Malaysia through its subsidiary CK Health, which aligns with the company's mission to expand holistic healthcare access [3][4]. Business Strategy - The new commercial distribution structure is designed to diversify EUDA's business and revenue streams, combining its holistic healthcare solutions with Guangdong Cell Biotech's established therapies [5].

Core Viewpoint - EUDA Health Holdings Limited is in preliminary discussions with Guangdong Cell Biotech to establish a joint venture aimed at enhancing growth and innovation in the biotechnology and consumer health sectors through a combined digital healthcare ecosystem and stem cell technology [2][4]. Company Overview - EUDA Health Holdings Limited operates a unique digital healthcare ecosystem in Southeast Asia, focusing on making healthcare affordable and accessible while improving patient outcomes through personalized healthcare solutions [6][7]. - Guangdong Cell Biotech is a leading enterprise in stem cell and regenerative medicine in China, with over 30 established treatment facilities and a strong focus on innovative therapies [8]. Strategic Rationale - The partnership aims to foster innovation in preventive healthcare by combining EUDA's digital healthcare expertise with Guangdong Cell Biotech's stem cell technology [5]. - The collaboration is expected to expand market presence and generate operational synergies, enhancing efficiency and improving patient outcomes [5]. - The joint venture seeks to accelerate the research and application of "digital + stem cell" technologies, aiming to set a new industry standard in healthcare [5]. Market Potential - The market for stem cell treatment in China and Asia is described as massive, indicating significant growth opportunities for both companies through this potential partnership [5].

Exhibit 99.1 EUDA HEALTH HOLDINGS LIMITED AND SUBSIDIARIES UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS | | | June 30, | | December 31, | | | --- | --- | --- | --- | --- | --- | | | | 2024 | | 2023 | | | ASSETS | | | | | | | CURRENT ASSETS | | | | | | | Cash | $ | 376,206 | $ | 189,005 | | | Accounts receivable, net | | 176,988 | | 237,474 | | | Prepayments | | 150,966 | | | - | | Other receivables | | 19,293 | | 1,711 | | | Other receivable, related party | | 20,557 | | | - | | Prepaid expenses and othe ...

Financial Performance - The company reported a net loss of approximately $8.5 million for the year ended December 31, 2023, compared to a net loss of $25.0 million for 2022[31]. - Revenue for the year ended December 31, 2023, decreased by approximately $58,000 or 1.5%, to approximately $3.7 million compared to $3.8 million in 2022[224]. - Gross profit for 2023 was $842,075, a decrease of $27,924 or 3.2% from $869,999 in 2022[223]. - Loss from operations improved to $(3,961,054) in 2023, a reduction of $8,258,203 or 67.6% compared to $(12,219,257) in 2022[223]. - Net loss for 2023 was $(10,036,104), a decrease of $14,913,142 or 59.8% from $(24,949,246) in 2022[223]. - General and administrative expenses decreased by $1,545,479 or 26.6% to $4,269,567 in 2023 from $5,815,046 in 2022[223]. - Other expense, net improved to $(4,473,727) in 2023, a decrease of $8,335,710 or 65.1% from $(12,809,437) in 2022[223]. - The company recorded no earnout share payment in 2023, a decrease of 100% from $5,199,629 in 2022[223]. - The company reported no impairment loss of long-lived assets in 2023, a decrease of 100% from $1,139,016 in 2022[223]. Operational Changes - The company streamlined its medical service operations by closing clinics in September 2023 due to lower demand in the post-Covid-19 era, which significantly impacted financial results[29]. - In September 2023, EUDA streamlined its medical service operations by closing clinics to reduce overhead costs, while actively seeking new investments and medical licenses for future healthcare services[80]. - The company is actively seeking new investments and medical licenses to acquire or develop other healthcare services following the streamlining of certain medical-related business units[215]. Funding and Capital Structure - The company raised an aggregate of $790,000 from the sale of 790,000 shares at $1.00 per share between May and July 2023[36]. - The company may face significant dilution of existing shareholders if additional funds are raised through equity or convertible debt securities[38]. - The company has experienced recurring losses and negative cash flows from operations since 2020, indicating a need for additional funding to support expansion plans[31]. Market and Competitive Landscape - EUDA faces significant competition in the digital healthcare market, which may impact its ability to maintain market share and profitability[63]. - The digital health industry is still evolving, and EUDA's growth may be adversely affected if market demand does not develop as expected[52]. - EUDA's revenue is significantly reliant on corporate clients in Singapore, with a high concentration risk that could affect growth if key clients are lost[56]. - EUDA's business model relies heavily on client acquisition costs, which may not be recoverable if client relationships are not maintained, potentially impacting financial results adversely[51]. Technology and Innovation - EUDA's platform integrates AI and ML to enhance healthcare services, providing real-time analytics and predictive analysis for better patient outcomes[126]. - The platform leverages AI and ML capabilities to improve patient outcomes, utilizing a database of at least 1,000 common diagnostic patterns[180]. - The company is investing in AI technology to improve patient engagement and care coordination[169]. Regulatory and Compliance Risks - Material weaknesses in internal control over financial reporting were identified, raising concerns about the reliability of financial statements[32]. - The uncertain regulatory environment may require EUDA to modify its offerings, potentially leading to revenue declines and operational challenges[112]. - EUDA's digital health offerings are subject to evolving government regulations, which may require compliance changes that could increase operational costs[113]. Client and Market Strategy - EUDA's marketing efforts significantly depend on positive references from existing clients; loss of long-term clients could harm the Company's reputation and revenue[86]. - Maintaining brand awareness is critical for EUDA's growth, and failure to do so could adversely impact the Company's operational and financial performance[83]. - EUDA's growth strategy depends on establishing and maintaining relationships with third-party providers, which is critical for service delivery[70]. International Expansion - The company aims to expand its operations across Southeast Asia, focusing on providing personalized healthcare through its proprietary platform[124]. - EUDA plans to expand its presence in Southeast Asia, targeting underdeveloped health and wellness verticals to capture market share[178]. - The company intends to expand internationally, exploring joint offerings and strategic acquisitions in Southeast Asia[168]. Human Resources - The company had 106 full-time employees as of December 31, 2023, with no labor relations issues reported[196]. - The management team has limited experience managing a public company, which could adversely affect the company's operations and financial condition[39]. - The company’s management team possesses extensive experience in property management, which is crucial for delivering superior products and services[218].

Singapore, May 08, 2024 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited ("EUDA" or the "Company") (NASDAQ:EUDA), a Singapore-based health technology company that operates a first-of-its-kind Southeast Asian digital healthcare ecosystem, proudly announces the successful completion of its acquisition of CK Health Plus Sdn Bhd ("CK Health") today. This strategic move marks an expansion of EUDA's presence in Malaysia and underscores its commitment to revolutionizing the healthcare landscape in the region. CK H ...

SINGAPORE, May 06, 2024 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited ("EUDA" or the "Company") (NASDAQ:EUDA), a Singapore-based health technology company that operates a first-of-its-kind Southeast Asian digital healthcare ecosystem, today announced that it will acquire CK Health Plus Sdn Bhd ("CK Health"), a direct seller of holistic wellness consumer products in Malaysia. Under the terms of the acquisition agreement, EUDA has agreed to acquire the entire issued capital of CK Health for an aggregate sh ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-40678 EUDA HEALTH HOLDINGS LIMITED (Exact Name of Registrant as Specified in Its Charter) British Virgin Islands n/a FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended March 31, 2023 (State or other jurisd ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 1 Pemimpin Drive #12-07 One Pemimpin Singapore 576151 (Address of principal executive offices and Zip Cod ...